-
1 Comment
Neoleukin Therapeutics, Inc is currently in a long term downtrend where the price is trading 25.7% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Neoleukin Therapeutics, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 310.8% to $-33M since the same quarter in the previous year.
Finally, its free cash flow fell by 82.4% to $-10M since the same quarter in the previous year.
Based on the above factors, Neoleukin Therapeutics, Inc gets an overall score of 1/5.
Sector | Healthcare |
---|---|
Industry | Biotechnology |
Exchange | NASDAQ |
CurrencyCode | USD |
ISIN | US64049K1043 |
Market Cap | 8M |
---|---|
PE Ratio | None |
Target Price | 1.5 |
Beta | 1.1 |
Dividend Yield | 0.0% |
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for NLTX using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025